• FEATURED

    Cancer Management CME Online Bundle: Comprehensive Review – Journal Summaries – $500 Amazon Gift Card

    The Cancer Management CME Online Bundle includes:
    • From CMEinfo Radiation Oncology – A Comprehensive Review led by Christopher G. Willett, MD, and featuring lectures for an all-encompassing clinical update
    • From Practical Reviews A one-year subscription, including our FREE mobile app
    • A $500 Amazon.com gift card
    • Unbiased content to help you prep for the boards and stay current without the need for travel or time away from your practice
    • Instant online access to key clinical updates to improve overall patient care
    • The opportunity to earn up to 82.25 AMA PRA Category 1 Credits combined

    Target Audience: Oncologists (especially Radiation Oncologists).

    • Cost: $1595
    • Credit hours: 82.25
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Format: On-Demand Online, Online Video
    • Material last updated: November 30, 2016
    • Expiration of CME credit: November 30, 2019
  • Practical Reviews in Cancer Management

    Practical Reviews in Cancer Management keeps you informed of the most important research and clinical findings published in Cancer Management each month.

    Each issue contains: downloadable audio of 12-15 articles summarized and reviewed in each issue; downloadable PDF of written reviews with Take-Home Pearls that reinforce the audio material and give you a valuable reference for instant recall by subject; and self-assessment online quizzes to highlight key points and reinforce what you’ve learned.

    Target Audience: Oncologists

    • Cost: $549 - $1,098
    • Credit hours: 56
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Format: On-Demand Online, Mobile App, Audio CD
    • Material last updated: Updated Monthly
    • Expiration of CME credit: Two years after date of publication
  • FEATURED

    BoardVitals Hematology/Oncology CME Self-Assessment and MOC Preparation Program ($200 OFF – Limited Time Only!)

    Complete your Hematology/Oncology CME requirements with the BoardVitals Hematology/Oncology CME Self-Assessment Program.
    • Earn 27 Hematology/Oncology CME Category 1 Credit Hours AND 27 ABIM Approved MOC Points, all while preparing for the recertification exam.
    • Access to more than 500 Hematology/Oncology CME questions, answers, and explanations
    • Each question is categorized – select the categories and areas that you want to focus on
    • Timed Mode and Review Mode available
    • Available from any computer or smartphone. Use anytime, anywhere.

    Upon completion of the BoardVitals Hematology/Oncology CME Self-Assessment Program, you will be able to:
    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

    Target Audience:
    Hematologists and Oncologists meeting CME requirements or preparing for the Hematology or Oncology Recertification Exams.

    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: University of Nebraska Medical Center
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FREE

    Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly–Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

    Metastatic Melanoma: Novel Approaches discusses the epidemiology, causes, clinical features, pathogenesis and immunotherapy in the treatment of metastatic melanoma.

    By the end of Metastatic Melanoma: Novel Approaches, you will be able to:
    • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
    • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe emerging (investigational) therapies for metastatic melanoma
    • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

    Target Audience:
    Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.

    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 4, 2017
    • Expiration of CME credit: December 4, 2019
  • FREE

    Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy

    The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients.

    By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
    • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
    • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
    Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
    • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

    Target Audience:
    Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 17, 2017
    • Expiration of CME credit: November 17, 2019
  • FREE

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics consists of a single presentation with discussion featuring Drs. Bradley J. Monk, MD and Robert L. Coleman, MD.

    At the conclusion of Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics, you will be able to:
    • Appraise the pathophysiology of ovarian cancer and their associated mutations, including germline and somatic BRCA mutations and other DNA repair deficiencies such as loss of heterozygosity
    • Evaluate the safety and efficacy data of PARP inhibitors
    • Use the latest diagnostic tools and genetic testing to identify patients who would benefit from PARP inhibitor therapy

    Target Audience:
    This program is intended for Medical and gynecologic oncologists, oncology nurses, nurse practitioners, pharmacists, and other health care professionals, including gynecologists, primary care physicians, physicians-in-training, and physician assistants involved in and/or interested in the management of patients with ovarian cancer.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: October 20, 2017
    • Expiration of CME credit: April 20, 2018
  • FREE

    Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies

    Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).

    By the end of Advances in Treating Metastatic Colorectal Cancer (CRC), you will be better able to:
    • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
    • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
    • Describe the challenges and barriers to care associated with treating patients with mCRC

    In order to receive credit from ScientiaCME, you must first establish a username and password.

    Target Audience:
    Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 19, 2017
    • Expiration of CME credit: October 19, 2019
  • FREE

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

    By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

    Target Audience:
    Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 02, 2017
    • Expiration of CME credit: November 02, 2019
  • FREE

    New Horizons in Personalized Care for Metastatic Bladder Cancer

    New Horizons in Personalized Care for Metastatic Bladder Cancer consists of a single lecture, New Horizons in Personalized Care for Metastatic Bladder Cancer with discussion by Matthew I. Milowsky, MD and Matthew Galsky, MD.

    After viewing New Horizons in Personalized Care for Metastatic Bladder Cancer, you will be better able to:
    • Evaluate the role of new targeted and immune-based agents in the first- and second-line metastatic settings, and how they can be integrated into practice
    • Apply strategies and tools that enhance patient-clinician communication and shared decision making processes

    Target Audiences:
    This program is intended for Medical/genitourinary oncologists, urologists, surgeons, radiologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with bladder cancer.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Albert Einstein College of Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: August 11, 2017
    • Expiration of CME credit: February 11, 2018
  • FREE

    Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions

    Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions consists of two lectures with discussion, Effective Management Strategies for Head and Neck Cancer and The New Paradigm of Immunotherapy for Head and Neck Cancer, both with Robert I. Haddad, MD and Jared Weiss, MD.

    After viewing Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions, you will be better able to :
    • Assess the safety and efficacy of available and emerging multimodal regimens, including immunotherapy, for patients with head and neck cancer
    • Utilize strategies to optimally sequence available regimens for the therapeutic management of head and neck cancer
    • Evaluate the latest clinical efficacy and safety data on the use of immune checkpoint inhibitors in head and neck cancer
    • Examine anticipated adverse events related with immune checkpoint inhibitors in head and neck cancer

    Target Audience:
    This program is intended for medical and radiation oncologists, head and neck surgeons, otolaryngologists, ear, nose and throat (ENT) specialists, and other health care professionals (primary care providers, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with head and neck cancer.

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: August 24, 2017
    • Expiration of CME credit: February 24, 2018